2-year survival outcomes of atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer with high tumor mutation burden: TELMA trial final report


Por: Pulla M, Granados A, Sarto J, de Juan V, Fabregat R, Gomez M, Guirado M, Carcereny E, Nunez N, Cabellos R, Guerrero R, Mateos L, Torres J, Sureda B, Sullivan I, Dols M, Hernandez A, Cabrera C, Cruz-Bermudez A

Publicada: 1 mar 2025
Resumen:

ISSN: 15560864





Journal Of Thoracic Oncology
Editorial
ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 20 Número: 3
Páginas:
WOS Id: 001502812600069

MÉTRICAS